Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy.
about
HIV-1 pol diversity among female bar and hotel workers in Northern TanzaniaMinor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patientsPairwise and higher-order correlations among drug-resistance mutations in HIV-1 subtype B protease.Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscapeDecreased emergence of HIV-1 drug resistance mutations in a cohort of Ugandan women initiating option B+ for PMTCT.Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitorsGenotypic testing for human immunodeficiency virus type 1 drug resistance.High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.Molecular epidemiology of HIV type 1 in newly diagnosed patients in southern Spain.Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitorsHIV-1 drug resistance in recently HIV-infected pregnant mother's naïve to antiretroviral therapy in Dodoma urban, Tanzania.Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.Drug resistance mutations in HIV pol sequences from Argentinean patients under antiretroviral treatment: subtype, gender, and age issues.Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France.Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patientsR57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen.HIV-1 drug resistance mutations: an updated framework for the second decade of HAARTActive-site mutations in the South african human immunodeficiency virus type 1 subtype C protease have a significant impact on clinical inhibitor binding: kinetic and thermodynamic study.Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDSMutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients.Prevalence of drug-resistant human immunodeficiency virus type 1 in therapy-naive patients and usefulness of genotype testing.Effectiveness of commercial inhibitors against subtype F HIV-1 protease.Impact of genetic variation of HIV-1 on drug resistance development
P2860
Q28540536-2E9B883F-52EA-43DF-BF83-FA4236576180Q28728304-443EE67D-92F3-4A94-972D-D90052B179CAQ33503921-0757D42F-437B-46B0-A511-E84D32797D14Q33648513-6972592C-95BD-44A1-96EE-21B36FC1A087Q33745946-EDD7A148-DD01-4749-8D21-339EEA2D05C5Q33770040-6FDC27A2-B45B-408B-8D4F-E6619A82D80FQ33906239-6502D810-7965-4FB9-BC48-1FFD31BBEFE6Q33911980-8D225243-44F3-48C4-A1DA-A8CF8D909E1FQ34080813-1FE9A40E-F4D5-438E-9D31-4A99AF5825F5Q34717615-EB38C2A4-9783-40EC-A2BB-7B4428614DF3Q34993070-4A054EB3-7A24-41CE-981D-9079835C66BEQ36099251-DB5F039D-0A33-4838-86A1-4CF64ED75FD4Q36102584-61032F47-0EF1-45B4-929C-88F2523C10A3Q36239954-B72F55EC-ABB5-4825-8F52-02CD086A68BFQ36367759-6D9DD823-5125-4534-AA88-4C426A640CAEQ36880577-554AC4F6-699D-49B9-BE58-FE953DEADED7Q36900010-57F94B9B-D55E-4FB1-B9CE-7A6E7BF166E7Q36949858-39945BCC-4057-4011-B60A-4DB72C8C6F08Q38708006-46E9A07B-7A25-4F84-A5BE-D116F923BBAAQ40800372-C85DFB1A-E181-4FC7-B6A6-90FD0DEBE000Q44572163-EFE346E3-F880-4501-B6B4-DDF049B8B4D6Q46339842-ABFE63AC-AAA9-4545-BE6D-D4A9FCB97E5BQ56778296-849C7590-E31A-41AB-AC2E-02163BB1DC9C
P2860
Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Secondary mutations in the pro ...... tease inhibitor-based therapy.
@en
Secondary mutations in the pro ...... tease inhibitor-based therapy.
@nl
type
label
Secondary mutations in the pro ...... tease inhibitor-based therapy.
@en
Secondary mutations in the pro ...... tease inhibitor-based therapy.
@nl
prefLabel
Secondary mutations in the pro ...... tease inhibitor-based therapy.
@en
Secondary mutations in the pro ...... tease inhibitor-based therapy.
@nl
P2093
P50
P356
P1476
Secondary mutations in the pro ...... tease inhibitor-based therapy.
@en
P2093
A Cozzi-Lepri
A N Phillips
A Scalzini
A Vincenti
A d' Arminio Monforte
F Dianzani
P304
P356
10.1086/323604
P407
P577
2001-08-30T00:00:00Z